読み込み中
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
前日終値
$0.9163
−$0.0314 · -3.31%
市場前
$0.9201
+$0.0038 · +0.41%
10月12日 7:06 ET
日中の時刻はETです。市場データは遅延する場合があります。
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
日中レンジ
現在 $0.9163
52週レンジ
現在 $0.9163
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
36
割高
センチメント
47
まちまち
リスク
70
高リスク
モメンタム
39
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
日中レンジ
現在 $0.9163
52週レンジ
現在 $0.9163
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 2566.29万 USD | 4822.48万 USD | 2945.87万 USD | 4730.61万 USD | 4493.65万 USD |
| 販売・一般管理 | 960.24万 USD | 1189.22万 USD | 1333.54万 USD | 1537.39万 USD | 1128.3万 USD |
| 営業費用 | 3526.52万 USD | 6011.7万 USD | 4279.41万 USD | 6268万 USD | 5621.95万 USD |
| 受取利息 | 332.39万 USD | 619.18万 USD | 732.3万 USD | 234.94万 USD | 18.54万 USD |
| 支払利息 | 190.53万 USD | 192.62万 USD | 207.1万 USD | 169.41万 USD | 174.21万 USD |
| 減価償却費と償却費 | 25.2万 USD | 24.96万 USD | 26.28万 USD | 25.87万 USD | 26.42万 USD |
| 営業利益 | −3526.52万 USD | −6011.7万 USD | −4279.41万 USD | −6268万 USD | −5621.95万 USD |
| 純利益 | −3384.67万 USD | −5585.14万 USD | −3754.25万 USD | −6202.46万 USD | −5777.63万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
